LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 6 of 15: Mean cell count and mean growth rate across biological replicate 3. - Dataset (ID:20242)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Dasatinib | 3.33 | uM | LJP6 | 72 | hr | 1401 | 2483 | 4223 | 0.5880 | 0.3834 |
| SK-BR-3 | Dovitinib | 3.33 | uM | LJP5 | 72 | hr | 1401 | 2108 | 4223 | 0.4992 | 0.2505 |
| SK-BR-3 | Enzastaurin | 3.33 | uM | LJP5 | 72 | hr | 1401 | 4584 | 4223 | 1.0855 | 1.1279 |
| SK-BR-3 | Erlotinib | 3.33 | uM | LJP5 | 72 | hr | 1401 | 3721 | 4223 | 0.8812 | 0.8222 |
| SK-BR-3 | Foretinib | 3.33 | uM | LJP5 | 72 | hr | 1401 | 1485 | 4223 | 0.3518 | 0.0298 |
| SK-BR-3 | R406 | 3.33 | uM | LJP6 | 72 | hr | 1401 | 4528 | 4223 | 1.0722 | 1.1081 |
| SK-BR-3 | Pictilisib | 3.33 | uM | LJP6 | 72 | hr | 1401 | 1576 | 4223 | 0.3732 | 0.0618 |
| SK-BR-3 | Gefitinib | 3.33 | uM | LJP6 | 72 | hr | 1401 | 2599 | 4223 | 0.6155 | 0.4245 |
| SK-BR-3 | Geldanamycin | 3.33 | uM | LJP5 | 72 | hr | 1401 | 1064 | 4223 | 0.2520 | -0.1195 |
| SK-BR-3 | Geldanamycin | 3.33 | uM | LJP6 | 72 | hr | 1401 | 1189 | 4223 | 0.2817 | -0.0751 |
| SK-BR-3 | GSK1059615 | 3.33 | uM | LJP5 | 72 | hr | 1401 | 995 | 4223 | 0.2356 | -0.1441 |
| SK-BR-3 | GSK1059615 | 3.33 | uM | LJP6 | 72 | hr | 1401 | 956 | 4223 | 0.2265 | -0.1577 |
| SK-BR-3 | GSK1904529A | 3.33 | uM | LJP6 | 72 | hr | 1401 | 4252 | 4223 | 1.0069 | 1.0104 |
| SK-BR-3 | Omipalisib | 3.33 | uM | LJP6 | 72 | hr | 1401 | 924 | 4223 | 0.2188 | -0.1692 |
| SK-BR-3 | GSK 690693 | 3.33 | uM | LJP5 | 72 | hr | 1401 | 3080 | 4223 | 0.7294 | 0.5950 |
| SK-BR-3 | GW843682X | 3.33 | uM | LJP6 | 72 | hr | 1401 | 1237 | 4223 | 0.2930 | -0.0582 |
| SK-BR-3 | HG-5-113-01 | 3.33 | uM | LJP5 | 72 | hr | 1401 | 1313 | 4223 | 0.3111 | -0.0311 |
| SK-BR-3 | HG-5-88-01 | 3.33 | uM | LJP6 | 72 | hr | 1401 | 3630 | 4223 | 0.8596 | 0.7898 |
| SK-BR-3 | Imatinib | 3.33 | uM | LJP6 | 72 | hr | 1401 | 4459 | 4223 | 1.0559 | 1.0837 |
| SK-BR-3 | JNK-9L | 3.33 | uM | LJP6 | 72 | hr | 1401 | 1163 | 4223 | 0.2755 | -0.0844 |
| SK-BR-3 | JW-7-24-1 | 3.33 | uM | LJP6 | 72 | hr | 1401 | 2131 | 4223 | 0.5048 | 0.2588 |
| SK-BR-3 | Lapatinib | 3.33 | uM | LJP6 | 72 | hr | 1401 | 1669 | 4223 | 0.3952 | 0.0948 |
| SK-BR-3 | LDN-193189 | 3.33 | uM | LJP5 | 72 | hr | 1401 | 1026 | 4223 | 0.2430 | -0.1330 |
| SK-BR-3 | Linifanib | 3.33 | uM | LJP6 | 72 | hr | 1401 | 4468 | 4223 | 1.0581 | 1.0869 |
| SK-BR-3 | Linsitinib | 3.33 | uM | LJP5 | 72 | hr | 1401 | 3443 | 4223 | 0.8154 | 0.7238 |